Figure 8From: ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedsideA model of enhanced STAT activation and overexpression of survivin leading to resistant phenotype in MV4–11-R cells. (Modified with permission from Blood journal) [50].Back to article page